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Endocrine therapy (ET) is the standard of care for
estrogen receptor-positive (ER+) breast cancers.
Despite its efficacy, 40% of women relapse with
ET-resistant (ETR) disease. A global transcription
analysis in ETR cells reveals a downregulation of the
neutral and basic amino acid transporter SLC6A14
governed by enhanced miR-23b-3p expression, re-
sulting in impaired amino acid metabolism. This
altered amino acid metabolism in ETR cells is sup-
ported by the activation of autophagy and the
enhanced import of acidic amino acids (aspartate
and glutamate) mediated by the SLC1A2 transporter.
The clinical significance of these findings is validated
by multiple orthogonal approaches in a large cohort
of ET-treated patients, in patient-derived xenografts,
and in in vivo experiments. Targeting these amino
acid metabolic dependencies resensitizes ETR cells
to therapy and impairs the aggressive features of
ETR cells, offering predictive biomarkers and poten-
tial targetable pathways to be exploited to combat
or delay ETR in ER+ breast cancers.INTRODUCTION
Themajority of breast tumors are positive for estrogen receptor a
(called hereafter ER) and/or progesterone receptor (PR) and
negative for human epidermal growth factor receptor 2 (HER2).
Since these tumors are dependent on estrogen for growth and
survival, inhibiting this dependency with endocrine therapies
(ETs) is the standard of care for these patients. ET agents include104 Cell Reports 28, 104–118, July 2, 2019 ª 2019 The Author(s).
This is an open access article under the CC BY-NC-ND license (http://selective ER modulators (e.g., tamoxifen) which compete with
estrogen for ER binding; selective ER downregulators (e.g., ful-
vestrant) that bind to and destabilize ER, inducing its degrada-
tion; and aromatase inhibitors (AIs; e.g., letrozole, anastrozole)
which block the conversion of androgens to estrogens lowering
estrogen levels. Over 50% of the ET-treated patients show an
initial clinical benefit, but 40% experience de novo or acquired
ET resistance (ETR). Therefore, there remains an urgent need for
more effective therapeutic strategies. We have previously
demonstrated that microRNA (miRNA)-dependent regulation of
the expression of key metabolic genes enhances glucose-
dependent metabolic plasticity in ETR cells (Bacci et al., 2016)
and that impairing this reprogramming resensitizes ETR cells to
therapy (Morandi and Indraccolo, 2017). Concomitantly, a num-
ber of metabolic stimuli (e.g., nutrients, hormones, cytokines)
modulate the miRNA expression, thus establishing a functional
association, which can be altered to perturb energy homeosta-
sis, as in the case of many tumors (Dumortier et al., 2013).
Here, we performed genome-wide expression profiling of ETR
long-term estrogen-deprived (LTED) ER+ breast cancer cells that
reveals a deregulation of amino acid transporters. Notably, the
mechanism that sustains amino acid metabolism in ETR is not
exclusively associated with estrogen deprivation but concurs
with fulvestrant and tamoxifen resistance, thus highlighting the
potential metabolic vulnerabilities to be exploited for either tar-
geting or prognostic purposes.
RESULTS
Genome Profiling Reveals a Deregulated miR-23b-3p/
SLC6A14 Axis in ETR Cells with Prognostic Value in ER+
Breast Cancer
To address the interconnection between miRNAs and genes
associated with estrogen deprivation, we analyzed the globalcreativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Global Gene Expression and
miRNA Analysis Reveals a Deregulated
miR-23b-3p/SLC6A14 Node in LTED Com-
pared to Parental MCF7 Cells
(A) Supervised hierarchical clustering of RNA
transcripts (left) and miRNAs (right) of 3 biological
replicates of MCF7, MCF7 deprived from estrogen
(E2) for 3 days, and LTED cells that were subjected
to gene or miRNA expression profiling using an
Agilent Technologies assay. Differentially ex-
pressed genes (n = 3,568; ANOVA) and miRNAs
(n = 62; ANOVA) were used for heatmap genera-
tion. High and low expression is normalized to the
average expression across all of the samples. On
the left side, association of the genes in the heat-
map with leading edge genes resulting from GSEA
analysis on the specified gene sets is identified.
(B) Gene set enrichment analysis enrichment plot
of amino acid transport dataset showing a negative
association between the MSigDb M188 dataset
and the LTED gene expression profile. NES,
normalized enrichment score.
(C) Anti-correlation network of differentially ex-
pressed miRNAs and mRNAs. Edge color is
proportional to the strength of the anti-correlation
(white to red = low to high). Node color is pro-
portional to the LTED versus MCF7 log fold
change (red, downregulated; green, upregulated).
Solute carrier (SLC) genes are labeled in black;
other miRNAs or mRNAs are labeled in gray. miR-
23b and SLC6A14 nodes are highlighted as large
circles.
(D and E) Kaplan-Meier analysis of overall survival
of BRCA TCGA cohort of ER+ patients divided into
high and low expressing, as described in Method
Details, for miR-23b-3p expression (D: TGCA, high
expressing, n = 68; low expressing, n = 475) or
SLC6A14 (E: TGCA, high expressing, n = 257; low
expressing, n = 467).gene and miRNA expression profile from 3 independent experi-
ments. We used an isogenic model in which parental MCF7 cells
in the presence of estrogen (E2) were used to model a patient at
primary diagnosis, MCF7 in the absence of E2 tomimic response
to an AI, and finally LTED MCF7 cells to model relapse on AIs.
Statistical analysis (1-way ANOVA, Benjamini-Hochberg correc-tion followed by Student-Newman-Keuls
post hoc tests; false discovery rate
[FDR] <0.05, fold-change >2 and <2) re-
vealed 62 miRNAs and 3,568 mRNAs
significantly deregulated in MCF7-LTED
versus MCF7, with or without E2. Within
the parental MCF7 cells, 603 genes and
14 miRNAs were found differently regu-
lated upon E2 treatment (Table S1). Su-
pervised hierarchical cluster analysis
shows comparable clustering of both
miRNA and gene expression data, with a
clear separation between MCF7-LTED
samples and the parental MCF7 cells
subdivided into E2-treated and short-term E2-deprived samples (Figure 1A). Although E2 treatment
had, as expected, a significant impact on gene expression (Table
S1), we focused on the differences between LTED and parental
MCF7 cells either in the presence or absence of E2 addition
to model a clinical scenario that is independent of circulating
E2 levels or prior endocrine agent administration, such as thatCell Reports 28, 104–118, July 2, 2019 105
of a post-menopausal patient who relapses after AI treatment
(Table S1).
Using gene set enrichment analysis (GSEA) (Subramanian
et al., 2005) (Table S2), many of the differentially expressed
gene sets in LTED versus MCF7 cells are related to metabolic
pathways (Figure 1A). In particular, the LTED profile is negatively
correlated with the gene set associated with amino acid trans-
porters and metabolism (Figure 1B). Since miRNAs exert their
role by binding to the target mRNAs and impairing their transla-
tion, their expression profiles are expected to be inversely corre-
lated. Therefore, we created a correlative network based on
gene andmiRNA expression profiles to identify potential deregu-
latedmiRNA-mRNA nodes (Figure 1C). Since the identification of
metabolic dependencies could be of therapeutic and predictive
value in ER+ breast cancer and GSEA analysis revealed deregu-
lated amino acid transport associated with LTED, we focused
our attention on a metabolic-related network involving the solute
carrier (SLC) family 6 member 14 (SLC6A14), a sodium-chloride-
dependent amino acid transporter for all of the amino acids, with
the exception of glutamate and aspartate (Babu et al., 2015). The
SLC family plays a significant role in mediating amino acid trans-
port across the plasma membrane (Hediger et al., 2004). Among
the miRNAs reported to correlate with SLC6A14 (Figure S1A)
was miR-23b-3p, which, as expected, showed an inverse corre-
lation (Bisognin et al., 2012). Furthermore, miR-23b-3p was
significantly upregulated in LTED cells compared to the parental
MCF7 cells, independently of E2 treatment (Table S1). The clin-
ical relevance of the deregulated miR-23b-3p/SLC6A14 node
observed was validated in retrospective clinical data. High
expression of miR-23b-3p correlates with reduced survival in
ER+ breast cancer patients (hazard ratio [HR] = 2.64, log-rank
p = 0.0007, n = 543; Figure 1D). Conversely, high expression of
SLC6A14 identifies a subset of good-prognosis ER+ breast can-
cer patients (HR = 0.47, log-rank p = 0.0012, n = 724; Figure 1E).
Similar results were obtained in an independent cohort of ER+
breast cancers (Figures S1B and S1C). A correlation analysis
between miR-23b-3p and SLC6A14 was performed on the
TCGA patients’ dataset selected based on higher (upper quar-
tile) and lower (lower quartile) expression levels of miR-23b-3p
(n = 104). The correlation is significant and negative, and,
crucially, SLC6A14 expression is completely lost in the high
miR-23b-3p-expressing tumors (Figure S1D).
miR-23b-3p and SLC6A14 Expression Is Deregulated in
ETR Models
To determine whether the deregulation of the miR-23b-3p/
SLC6A14 expression axis was a prerequisite of cells that are
resistant to E2 deprivation or more generally a feature of ETR
cells, we evaluated their expression in the LTED cells and in
the MCF7-TAMR and MCF7-FULVR cell lines that are MCF7 de-
rivatives, mimicking the acquired resistance to tamoxifen and
fulvestrant, respectively. qRT-PCR analysis revealed a signifi-
cant increase in the expression of miR-23b-3p (Figure 2A) and
the reduced expression of SLC6A14 (Figures 2B–2D) in all of
the ETR lines when compared to their parental counterpart.
The miR-23b-3p mimic construct transfected into parental cells
(Figure S2A) induced SLC6A14 downregulation (Figure 2E),
whereas the miR-23b-3p inhibitor transfected into LTED cells106 Cell Reports 28, 104–118, July 2, 2019(Figure S2B) led to an SLC6A14 increase, thereby demonstrating
the functional relation between miR-23b-3p and SLC6A14 (Fig-
ure 2E). Consistent with reduced SLC6A14 expression, all of
the ETR cells displayed a reduced uptake of exogenous 14C-
labeled amino acidswhen compared to the parental cell counter-
parts (Figures 2F–2H). This impairment in amino acids uptake
could be reversed by downregulating miR-23b-3p expression
(Figures 2I and S2B). However, despite the reduced amino acids
uptake, no significant difference was observed in de novo pro-
tein synthesis (Figure 2J), suggesting nomajor impact on protein
availability to support ETR cell growth. Moreover, anti-miR-23b-
3p treatment slightly but significantly impaired LTED and TAMR
MCF7 cell survival (Figures S2C and S2D).
GATA2 Is Enhanced during ETR and Controls miR-23b-
3p-Dependent Amino Acids Upload
GATA2 is a transcription factor involved in embryonic develop-
ment, self-renewal, and stemness found overexpressed and
involved in cancer (Rodriguez-Bravo et al., 2017). GATA2
expression is negatively controlled by E2 (Yang et al., 2017),
and miR-23b-3p is a putative target of GATA2 (JASPAR
Predicted Transcription Factor Targets, http://amp.pharm.
mssm.edu/Harmonizome). GATA2 expression was significantly
enhanced in ETR cells both at the protein and mRNA levels (Fig-
ures 3A and 3B). E2 deprivation induced enhanced GATA2
expression (Figures 3C and 3D) and the subsequent increase
in miR-23b-3p expression (Figure 3E) in the parental cells, thus
reinforcing the functional link between E2 deprivation, GATA2,
and miR-23b-3p that characterized E2-deprived and endocrine
agent-treated cells. Silencing GATA2 in all of the high-express-
ing ETR cells (Figure S3A) resulted in reduced miR-23b-3p
expression (Figure 3F), enhanced amino acids uptake (Fig-
ure 3G), and impaired cell survival (Figure 3H). The clinical signif-
icance of GATA2 in ER+ breast cancer was validated in a large
retrospective breast cancer patient cohort in which GATA2
higher expression identifies a subset of ER+ breast cancers char-
acterized by poorer prognosis (HR = 1.86, log-rank p = 0.0008,
n = 548; Figure 3I).
Enhanced Autophagic Flux Is Essential for ETR Cell
Survival
Despite the reduced amino acids uptake in ETR cells, we did not
observe a significant reduction in cell growth, protein synthesis,
or protein content between LTED and parental cells (Figures 2J,
S4A, and S4B). Therefore, we hypothesized that LTED cells may
compensate for decreased amino acids uptake by activating
macro-autophagy, hereafter referred as autophagy. Autophagy
allows a cell to recycle dispensable and/or dysfunctional compo-
nents to fuel catabolic and anabolic processes, including protein
synthesis (Galluzzi et al., 2015). Moreover, SLC6A14 downregu-
lation has been reported to induce autophagy activation (Coo-
thankandaswamy et al., 2016). Western blot analysis revealed
that LTED cells have increased levels of the microtubule-associ-
ated protein 1A-1B-light chain 3 (LC3), an established marker of
autophagy activation, which was further enhanced by chloro-
quine (CQ) administration (Figure 4A). CQ is a lysosomotropic
agent that prevents endosomal acidification, hence inhibiting
lysosomal hydrolases and preventing autophagosomal fusion
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Figure 2. miR-23b-3p/SLC6A14 Axis Is De-
regulated in Different ETR Cells
(A–D) ETR-derived and parental MCF7 (A and B),
HCC1428 (C), and ZR75.1 (D) cells were subjected
to qRT-PCR analysis using the assays described
in the figure. Relative expression is shown using
the parental cells as comparator. Data represent
means ± SEMs. One-way ANOVA; Dunnett cor-
rected; *p < 0.05; **p < 0.01; ***p < 0.001. Each dot
represents a biological replicate.
(E) Total protein lysates fromMCF7 and LTED cells
transfected with the oligos as described in the
figure for 72 h were subjected to western blot
analysis, as indicated.
(F–H) 14C-amino acids mixture upload was
measured in ETR-derived and parental MCF7 (F),
HCC1428 (G), and ZR75.1 (H) cells. The relative
upload capacity is shown using parental cells as
comparator. Data represent means ± SEMs. One-
way ANOVA; Dunnett corrected; *p < 0.05; **p <
0.01; ***p < 0.001. Each dot represents a biological
replicate.
(I) 14C-amino acids mixture upload was measured
in ETR-derived MCF7 cells transfected for 72 h
with either anti-miR-CTR or anti-miR-23b-3p oli-
gos. The relative upload capacity is shown using
anti-miR-CTR transfected cells as comparator.
Data represent means ± SEMs. Student’s t test;
*p < 0.05; **p < 0.01; ***p < 0.001. Each dot rep-
resents a biological replicate.
(J) LTED derivatives and parental counterparts of
MCF7 and ZR75.1 cells were subjected to protein
synthesis assay, as described in Method Details.
No differences were observed between parental
and LTED cells in the absence or presence of the
protein synthesis inhibitor cycloheximide (CHX,
50 mg/mL for 30 min). Data represent means ±
SEMs. One-way ANOVA; Dunnett corrected; ns,
not significant.and degradation. Since autophagy is a dynamic process, acute
CQ administration results in the accumulation of autophago-
somes, and the observed LC3-II increase is thus directly corre-
lated with the autophagic flux (Yoshii and Mizushima, 2017).
Additional regulators of autophagy induction includemammalian
target of rapamycin (mTOR) inhibition and beclin-1 expression,
which functions as the central scaffold protein for autophago-
some formation. The 3 MCF7 ETR derivatives showed increased
levels of beclin-1 and LC3-II expression (Figure 4B). The auto-
phagy activation described is functionally linked to miR-23b-3p
expression, since ectopic miR-23b-3p overexpression in
parental MCF7 cells enhanced LC3-II (Figure 4C), whereas the
miR-23b-3p inhibitor reduced that of LTED cells (Figure 4D). In
addition, ETR cells showed an increased number of LC3 puncta
in the presence of CQ, when compared to parental cells (Figures
4E and 4F). Comparable results were obtained in ETR models of
ZR75.1 and HCC1428 cells when compared to their parental
counterparts (Figures 4F, S4C, and S4D). Based upon thisobservation, longer CQ treatment (120 h) or silencing ATG7, a
key component in the autophagosome formation, selectively
impaired cell survival in ETR cells (Figures 4G and S4E–S4H),
but not in the parental cells, indicating that targeting autophagy
may resensitize ETR cells to endocrine agents.
An additional indication that autophagy may play a key role in
ETR comes from the report that miR-23b-3p acts as a regulator
of beclin-1 (Gozuacik et al., 2017). Ubiquitination of beclin-1 on
Lys63 (K63) promotes autophagy, and this K63 ubiquitination
is controlled by the balanced action of the ubiquitinating enzyme
tumor necrosis factor receptor (TNFR)-associated factor 6
(TRAF6) and the deubiquitinating enzyme TNFAIP3 (also known
as A20) (Shi and Kehrl, 2010). Our analysis revealed that
TNFAIP3 is a predicted target gene of miR-23b-3p (using
miRGator3.0 [Cho et al., 2013], a positive score was found in
TargetScan, miRNAorg, PITA, PicTar, and miRDB). This interac-
tion has also been validated by cross-linking immunoprecipita-
tion (Kishore et al., 2011). Gene expression data (0.48-foldCell Reports 28, 104–118, July 2, 2019 107
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Figure 3. GATA2 Is Enhanced during ETR
andControlsmiR-23b-3p-DependentAmino
Acids Upload
(A) Total protein lysates from ETR-derived and
parental MCF7 cells were analyzed by western
blotting with the antibody indicated.
(B) ETR-derived and parental MCF7 cells were
subjected to qRT-PCR for GATA2 analysis. Rela-
tive expression is shown using the parental cells as
comparator. Data represent means ± SEMs. One-
way ANOVA; Dunnett corrected; *p < 0.05; **p <
0.01. Each dot represents a biological replicate.
(C–E) Parental MCF7 cells were 3-day E2 deprived
and subjected to either qRT-PCR (C and E) or
western blot (D) analyses, as indicated in the
figure. Data represent means ± SEMs. Student’s t
test; **p < 0.01; ***p < 0.001.
(F–H) ETR-MCF7 cell derivatives transfected with
non-targeting small interfering RNA (siRNA)
(siCTR) or siRNA targeting GATA2 (siGATA2) for
72 h were subjected to qRT-PCR analysis for miR-
23b-3p expression (F), 14C-amino acids upload
capacity (G), or cell viability assay using crystal
violet (H). siCTR transfected cells were used as
comparator. Data represent means ± SEMs. Stu-
dent’s t test; ***p < 0.001.
(I) Kaplan-Meier analysis of overall survival of ER+
breast cancer patients divided into high and low
GATA2 expressing, as described in Method De-
tails. Hazard ratio (HR) and log-rank Mantel-Cox
p values are shown.compared to MCF7E2 and 0.29-fold compared to MCF7+E2)
and qRT-PCR analysis demonstrated a reduction in the expres-
sion of TNFAIP3 in the LTED cells (Figure 4H). This reduced
expression is of clinical significance as low TNFAIP3 expression
identifies a poor prognosis subset of patients in independent
studies (HR = 0.52, log-rank p = 0.0066; Figures 4I and S1E).
In support of these data, immunoprecipitation and western blot
demonstrated an increase in not only the beclin-1 levels in the
3 ETR lines (see also Figure 4B) but also the level of K63-ubiqui-
nated beclin-1, thus sustaining autophagy in the ETR cells
(Figure 4J).
Increased Levels of Intracellular Aspartate and
Glutamate Sustain the Aggressive Phenotype of ETR
Cells
Despite the demonstration that ER+ cells are dependent on the
SLC6A14 transporter (Babu et al., 2015) and that all ETR cell lines108 Cell Reports 28, 104–118, July 2, 2019show a substantial reduction in SLC6A14
expression (Figures 2B–2D), it was
notable that ETR cells show only a
modest reduction in amino acids uptake
(Figures 2F–2H) and no significant differ-
ence in de novo protein synthesis (Fig-
ure 2J), suggesting no major impact on
protein availability to support ETR cell
growth (Figures S4A and S4B). To
determine whether the maintenance of
de novo protein synthesis was accompa-nied by an imbalance in the intracellular amino acid levels, we
analyzed their relative intracellular concentration in the LTED
and parental MCF7 cells. High-performance liquid chromatog-
raphy (HPLC) analysis revealed a significant increase in the intra-
cellular levels of aspartate and glutamate in MCF7-LTED cells
compared to parental cells (Figure 5A), and, moreover, the levels
of aspartate and glutamate were unaffected by acute CQ treat-
ment (Figure S4I). These analyses indicate that the increased
levels of aspartate and glutamate in LTED cells were not depen-
dent on the enhanced autophagic flux. By contrast, a general
decrease in essential amino acid intracellular levels was induced
by CQ (Figure S4I). We therefore hypothesized that an acidic
amino acid transporter may be expressed at higher levels in
the LTED model to provide the increased levels of aspartate
and glutamate. Gene expression analysis of LTED and parental
cells revealed 57 significantly deregulated SLC genes (Fig-
ure 5B), 9 of which encode amino acid transporters. Of these,
A C E
B D
F G
H I J
Figure 4. ETR Cells Rely on miR-23b-3p-
Dependent Autophagy Activation for Cell
Survival
(A) LTED and parental MCF7 cells were subjected
to 25 mmol/L chloroquine (CQ) for 16 h. Total
protein lysates were analyzed by western blotting
with the antibody indicated.
(B) Total protein lysates from ETR and parental
MCF7 cells were subjected to western blotting
analysis with the antibodies indicated.
(C and D) Total protein lysates from MCF7 (C) and
LTED (D) cells transfected with the oligos as
described in the figure for 72 h were subjected to
western blot analysis, as indicated.
(E and F) MCF7 ETR and parental (E) cells were
treatedwith 25mmol/L ofCQ for 16handsubjected
to confocal analysis (E, green: LC3; blue: TO-
PRO-3, nuclei). Comparable analysis was per-
formed for HCC1428-LTED (Figure S4C), ZR75.1-
LTED (Figure S4D), and parental counterparts, and
LC3 puncta were quantified (F) as described in
Method Details. Representative images are
shown; scale bar, 10 mm. Data represent means ±
SEMs. Two-way ANOVA; **p < 0.01; ***p < 0.001.
(G) ETR-derived and MCF7 parental cells were
grown either in the absence (vehicle) or presence
of 50 mmol/L CQ treatment for 120 h before sub-
jecting them to cell viability assay. Data are
presented as fold change survival fraction of CQ-
treated versus vehicle-treated cells. Representa-
tive images are shown. Data represent means ±
SEMs and were compared to parental cells using
1-way ANOVA; Dunnett corrected; ***p < 0.001.
(H) LTEDandMCF7parental cellsweresubjected to
qRT-PCRusing the assay indicated.Data represent
means ± SEMs. Student’s t test; ***p < 0.001.
(I) Kaplan-Meier analysis of overall survival of
BRCA The Cancer Genome Atlas (TCGA) cohort
of ER+ patients divided into high and low ex-
pressing, as described in Method Details for
TNFAIP3 expression (high expressing, n = 231;
low expressing, n = 493). The HR and log-rank
Mantel-Cox p value are shown.
(J) Total protein lysates from ETR and parental
MCF7 cells were subjected to immunoprecipita-
tion (IP) using an anti-beclin-1 antibody and then
subjected to immunoblotting (IB), as reported in
the figure (top). Total lysates were also subjected
to western blot analysis, as indicated (bottom).8 were downregulated in the LTED compared to parental cells,
including SLC6A14. The exception was SLC1A2, a sodium-
dependent high-affinity glutamate/aspartate transporter (3.4-
fold increased in LTED cells compared to MCF7E2 and
4.1-fold compared toMCF7+E2). Western blot and qRT-PCR an-
alyses confirmed SLC1A2 increased expression in the LTED
cells compared to their corresponding parental line (Figures 5B
and 5C), an observation that is independent of E2 stimulation
(Table S1). SLC1A2 has a predicted GATA2 binding site at the
promoter region (JASPAR Predicted Transcription Factor Tar-
gets, http://amp.pharm.mssm.edu/Harmonizome), and GATA2
silencing reduced SLC1A2 expression levels (Figure S3B).
SLC1A2 silencing further reduced the amino acids uptake of
ETR cells (Figures 5D and 5E), which was already diminishedcompared to parental cells (Figures 2F–2H). Furthermore,
SLC1A2 silencing impaired the incorporation by MCF7-LTED
cells of 14C-glutamate (Figure 5F) and 14C-aspartate (Figure 5G),
thus reducing ETR cell survival (Figure 5H) andMCF7-LTED inva-
sion (Figure S5A), an aggressive feature of LTED cells. In addi-
tion, LTED colony formation ability was reduced by selective
aspartate and glutamate deprivation (Figure 5I), thus reinforcing
the notion that the selective upload of aspartate and glutamate
drives the more ‘‘aggressive phenotype’’ of LTED cells.
Aspartate and Glutamate Confer Metabolic Plasticity to
ETR Cells
To identify the fate of the uploaded aspartate and glutamate,
we performed a radioactive tracing analysis. The enhancedCell Reports 28, 104–118, July 2, 2019 109
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Figure 5. Aspartate and Glutamate Intracel-
lular Levels Sustain the Aggressive Pheno-
type of ETR Cells
(A) Intracellular amino acids were extracted from
LTED and parental MCF7 cells. Amino acid deriv-
atization was performed using 4-N,N-dimethy-
laminoazobenzene-40-sulfonyl chloride (DABS).
DABS-amino acids were detected at visible light
wavelengths using HPLC. A representative chro-
matogram is reported, and the quantification of
aspartate (Asp) and glutamate (Glu) from 4 bio-
logical replicates is represented in a box and
whiskers graph (mean, 25th percentile, and 75th
percentile are shown; + indicates themedian of the
values). Student’s t test; ***p < 0.001.
(B) Gene expression analysis of the significantly
deregulated SLC transporters in LTED cells when
compared to parental cells. Of the 57 significantly
deregulated SLC genes, 9 amino acid transporters
are shown in red. Each dot represents the mean
value of the fold change derived by the analysis
of 3 biological replicates (see Figure 1). Western
blot analysis of total lysates from parental and
LTED MCF7 cells for SLC1A2 is reported in the
inset.
(C) LTED and parental MCF7, HCC1428, and
ZR75.1 cells were subjected to qRT-PCR using
the assay indicated. Data represent means ±
SEMs, n = 3. Student’s t test; *p < 0.05; ***p <
0.001.
(D–G) MCF7 ETR derivatives (D), HCC1428-LTED
(E), and MCF7-LTED (F and G) were silenced
using the non-targeting control (siCTR) or siRNAs
targeting SLC1A2 (siSLC1A2) for 72 h. 14C-amino
acid (D and E), 14C-glutamate (F), and 14C-aspar-
tate (G) uptake was measured, and the radioactive
signal normalized on protein content is shown,
using siCTR-treated cells as comparators. Data
represent means ± SEMs. One-way ANOVA;
Dunnett corrected; ***p < 0.001.
(H) Complementarily, cell viability was measured
using crystal violet staining and reported as fold
change using parental cells as comparator.
Data represent means ± SEMs. Student’s t test;
***p < 0.001.
(I) ETR and parental cells were subjected to colony formation assay either in the presence of all of the amino acids (all) or in the absence of both aspartate
and glutamate (Asp, Glu), as described in Method Details. Data represent means ± SEMs of 3 biological replicates. Two-way ANOVA; Bonferroni
corrected; *p < 0.05.incorporation of radioactive aspartate observed in ETR cells (Fig-
ures 6A and S6A) was paralleled by the increased radioactive
labeling of lipids (Figure 6B), proteins (Figure 6C), and DNA (Fig-
ure 6D) in ETR cells (Figures S6B–S6D). Conversely, the
enhanced incorporation of glutamate in ETR cells (Figures 6E
and S6E) was paralleled only by a significant increase in radioac-
tive DNA labeling (Figure 6H), although a tendency toward
enhanced radioactive lipids and proteins was observed in ETR
cells (Figures 6F, 6G, S6F, and S6G). To quantify the contribution
of aspartate and glutamate to the LTED metabolism, cells were
cultured in medium containing uniformly (U) labeled 13C-aspar-
tate (Figure 6I) or 13C-glutamate (Figure 6J), and the 13C-labeling
of the tricarboxylic acid (TCA) cycle intermediates, together with
metabolites that could act as precursors of anaplerotic reactions
(e.g., uridine-50-triphosphate [UTP] for DNA synthesis and gluta-110 Cell Reports 28, 104–118, July 2, 2019mine for protein synthesis), were analyzed by liquid chromatog-
raphy-mass spectrometry (LC-MS). When U-13C-aspartate
was used, significant increases in 13C-labeled a-ketoglutarate
(a-KG), succinate, malate, oxaloacetate, and citrate were
observed in LTED cells when compared to the parental cell
counterpart (Figure 6I). This was paralleled by a significant label-
ing of UTP and glutamine, indicating that aspartate is a major
source of carbons for the TCA cycle and this could fuel anabolic
pathways. Isotopologues analysis revealed that the TCA cycle in
LTED cells occurs predominantly via canonical cycle activity,
since a considerable fraction of citrate was 4 atoms of 13C,
whereas the fraction of 5 atoms is limited, suggesting that reduc-
tive carboxylation of a-KG, although occurring in LTED cells, is
not their main feature (Figure 6I). Comparable results were ob-
tained when U-13C-aspartate was used in combination with
A B C D E F G H
I
J
K L
Figure 6. Metabolic Plasticity of ETR Cells Is Sustained by Aspartate and Glutamate
(A–D) LTED and MCF7 cells were subjected to 14C radioactive aspartate uptake (A) or cultured for 24 h in a medium containing radioactive aspartate. Lipids,
proteins, or DNAwere extracted in parallel and radioactive signal measured tomonitor the amount of aspartate that is incorporated into lipids (B), proteins (C), and
DNA (D), as described in Method Details. Each value was normalized on protein content.
(legend continued on next page)
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(unlabeled) 12C-glutamate (Figure S6I), suggesting that the ability
of aspartate to fuel the TCA cycle and subsequent anabolic and
catabolic pathways is independent of the presence of glutamate.
When U-13C-glutamate was used, significant increases in 13C-
labeled a-KG, succinate, malate, oxaloacetate, and citrate
were observed in LTED cells when compared to the parental
cell counterpart (Figure 6J). This was paralleled by a significant
labeling of UTP and glutamine, indicating that glutamate is a
source of carbons for the TCA cycle and that can fuel anabolic
pathways (Figure 6J). Similar to aspartate, comparable results
were obtained when U-13C-glutamate was used in combination
with 12C-aspartate (Figure S6J).
As ETR cells have enhancedmetabolic plasticity (Morandi and
Indraccolo, 2017), we next addressed whether their increased
aspartate and glutamate uptake was used, not only for anabo-
lism but also as a source of energy. As assessed using the Sea-
horse XFe Mito Stress Test (Figures 6K, 6L, S6K, and S6L), there
were no significant differences in basal and maximal respiration
by monitoring the oxygen consumption rate (OCR) of parental
MCF7 cells either in the presence or absence of single or both
amino acids. By contrast, concomitant deprivation of aspartate
and glutamate in ETR cells (Figures 6K, 6L, S6K, and S6L) signif-
icantly impaired their basal and maximal respiration. However,
the withdrawal of each single amino acid was not sufficient to
affect the OCR levels of ETR cells, suggesting that ETR cells
can replenish the TCA cycle and subsequent electron transport
chain with either amino acid, when the other is absent. This
is in line with the results of the metabolomic analysis using
U-13C-glutamate and U-13C-asparate (Figure 6I and 6J).
Increased Aspartate and Glutamate Levels in Patient-
Derived Xenografts (PDXs) Correlate with ETR, and
Impairing Their Transport Reduces the Metastatic
Potential of ETR Cells In Vivo
To further corroborate the role of the amino acid transporters in
our model, we monitored SLC6A14 and SLC1A2 in an estab-
lished ER+ breast cancer PDX model (HBCx34 TAMR), which
has acquired resistance to tamoxifen treatment in vivo (Cottu
et al., 2014). qRT-PCR analysis revealed a significant reduction
in SLC6A14 expression and a concomitant increase in SLC1A2
in the TAMRPDXswhen compared to the parental PDXs (Figures
7A and 7B). This differential SLC expression was accompanied
by enhanced intratumoral levels of glutamate and aspartate, as-
sessed using gas chromatography-MS (GC-MS) analysis (Fig-
ures 7C and 7D). Since we and others have previously reported
that ETR cells display enhanced invasive abilities in vitro and(E–H) LTED and MCF7 cells were subjected to 14C radioactive glutamate uptake
proteins, or DNA were extracted in parallel and the radioactive signal was mea
proteins (G), and DNA (H), as described in Method Details. Each value was norma
*p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant.
(I and J) Schematic overview of the metabolism of downstream 13C-labeled aspart
in the metabolites (I). Schematic overview of metabolism of downstream 13C-labe
glutamate in the metabolites (J). Two-way ANOVA, Sidak corrected; *p < 0.05; **
(K and L) Parental and LTEDMCF7 cells were subjected to Seahorse XFe96 Mito
time in the presence or absence of the indicated amino acids. Basal (K) and maxim
OCRafter the administration of the ATP synthase inhibitor oligomycin, the proton u
respiratory complex I inhibitor rotenone, together with the respiratory complex
Dunnett’s corrected; **p < 0.01.
112 Cell Reports 28, 104–118, July 2, 2019in vivo (Bacci et al., 2016; Nguyen et al., 2015; Liu et al., 2014),
we assessed whether impairing amino acid metabolism and
availability, by targeting SLC1A2 or miR-23b-3p, had an impact
on the invasive phenotype of the ETR cell lines, as observed
in vitro (Figures S5A and S5B). To directly assess the role of
the 3p isoform of the miR-23b, we could not stably express
the pre-miR-23b construct, as this results in the downregulation
of both the3p or5p isoforms. Therefore, we transfected cells
with either a control non-targeting miRNA (anti-miR-CTR) or an
anti-miR-23b-3p in a short-term in vivo assay, which has been
previously published to reflect the metastatic potential of breast
cancer cells (Murugaesu et al., 2014). Since metastatic burden
resulted from the ability of the cells to survive in the circulation
and to colonize secondary sites, transfected cells were labeled
with cell tracker dyes, mixed in a 1:1 ratio, and injected via the
tail vein into SCID mice. Imaging the lungs 1 h post-injection
confirmed that an equal number of cells had been inoculated.
An examination of the lungs 5 h post-injection revealed that a
reduced number of anti-miR-23b-3p-treated cells were retained
in the lungs compared to the anti-miR-CTR transfected cells,
indicating that miR-23b-3p expression is required for efficient
survival in the circulation and retention in the lungs (Figures 7E
and S7A). Equivalent results were obtained in a dye swap exper-
iment (Figure S7B). Crucially, comparable data were obtained by
targeting SLC1A2 (Figure 7F and S7C), indicating that both miR-
23b-3p and SLC1A2 are responsible for the increased invasive
ability of the ETR cells and that their targeting could reduce the
aggressiveness of ETR breast cancer.
Finally, we evaluated whether the molecular players differen-
tially expressed in ETR cells versus the parental counterpart
and involved in the described reprogramming could have prog-
nostic and predictive value for ET-treated ER+ breast cancers.
We used a curated dataset that combined800 ER+ breast can-
cer patients (from independent retrospective studies) who had
been treated with adjuvant tamoxifen. Relapse-free survival
was used as a surrogate for therapy response. Kaplan-Meier
analysis revealed that patients characterized by lower levels of
TNFAIP3 (HR = 1.64, p = 0.01, n = 809; Figure 7G) or SLC6A14
(HR = 1.69, p = 0.0029, n = 809; Figures 7G and 7H) showed
poorer relapse-free survival when compared with higher-ex-
pressing tumors. Multivariate Cox regression analysis revealed
that the prognostic value is independent of proliferation (Table
S3). The predictive value of SLC1A2 in response and resistance
to ET was validated by in silico analysis, which was performed by
retrieving publicly available gene expression data from the
biopsies of 52 ER+ breast cancer patients taken before and after(E) or cultured for 24 h in a medium containing radioactive glutamate. Lipids,
sured to monitor the amount of glutamate that is incorporated into lipids (F),
lized on protein content. Data represent means ± SEMs, n = 3. Student’s t test;
ate and fluxes and relative incorporation of 13C carbons derived from aspartate
led glutamate and fluxes and relative incorporation of 13C carbons derived from
p < 0.01; ***p < 0.001; ns, not significant.
Stress Test analysis and oxygen consumption rate (OCR) was measured in real
al (L) respiration was calculated as described in Method Details, based on the
ncoupler carbonilcyanide p-triflouromethoxyphenylhydrazone (FCCP), and the
III inhibitor antimycin A. Data represent means ± SEMs. One-way ANOVA;
A B C D
E F
G H I
J
Figure 7. Increased Aspartate and Glutamate Levels in PDX Correlate with ETR, and Impairing Their Transport Reduces the Metastatic
Potential of ETR Cells
(A–D) ET (i.e., tamoxifen)-sensitive and tamoxifen-resistant PDX (HBCx34) were obtained from ER+ breast cancer specimens previously characterized as
described in Method Details. Tumor tissues were excised, and total RNA was extracted and subjected to qRT-PCR using the assay to detect SLC6A14 (A) and
SLC1A2 (B). Each dot represents an independent mouse. Alternatively, tumor tissues were extracted and subjected to GC-MS (as detailed in Method Details) to
evaluate the intratumoral levels of glutamate (C) and aspartate (D). Data represent means ± SEMs. Student’s t test; *p < 0.05; **p < 0.01; ***p < 0.001.
(legend continued on next page)
Cell Reports 28, 104–118, July 2, 2019 113
2 weeks of neoadjuvant letrozole treatment (Miller et al., 2007).
The patients were divided into responders and non-responders,
defined by a >50% and a <50% reduction, respectively, in tumor
volume following a further 3 months of letrozole treatment. A
pairwise comparison shows a significant decrease in SLC1A2
expression after 2 weeks of letrozole treatment in the responder
cohort but not in the non-responder cohort (p = 0.0007; Figure 7I).
The relevance of the players involved in response to selective
downregulators of ER was finally validated in a small cohort of
ER+ breast cancer patients who received adjuvant fulvestrant.
Since the clinical outcome was not available, we used the
changes in the proliferation-related gene AURKA as a surrogate
for therapy response. The evaluation of proliferation using Ki67
staining has been shown to predict poor long-term disease
outcome (Forbes et al., 2008). Changes in the expression levels
of SLC1A2 induced by fulvestrant treatment were positively
correlated with those of AURKA (rs = 0.62, p = 0.05, n = 11; Fig-
ure 7J), suggesting that SLC1A2 expression levels are linked to
fulvestrant-induced changes in proliferation (i.e., response to
therapy).
These data support a role for amino acid metabolic reprog-
ramming in ETR breast cancers, and the predictive value of the
molecular and metabolic players identified should be validated
in clinical prospective (neoadjuvant) trials.
DISCUSSION
The data presented in this study highlight the amino acid meta-
bolic pathway as an important determinant of resistance to ET
in ER+ breast cancers. In particular, molecular reprogramming
occurs and sustains the catabolic and anabolic processes of
ETR breast cancer cells by (1) activating autophagy and (2)
modulating the expression of amino acid transporters to selec-
tively import certain amino acids (in this case, aspartate and
glutamate).
This study originated from the analysis of extensively charac-
terized ER+ cells adapted to study ETR that we along with others
have demonstrated to be clinically relevant (Martin et al., 2003,
2012; Nguyen et al., 2015; Sanchez et al., 2011; Morandi et al.,
2013; Fox et al., 2013; Plaza-Menacho et al., 2010; Liu et al.,
2014). In addition, in vitro findings were validated using PDX,
lung retention assay, and retrospective clinical data derived
from ET-treated patients.
miR-23b is a member of the miR-23b/-27b/-24-1 cluster, and
its deregulation has been reported in several types of cancer,
although no conclusive results to date have provided a link be-(E and F) MCF7-LTED cells were transfected with either anti-miR-23b-3p or a non
(green for anti-miR-CTR and red for anti-miR-23b-3p) before injecting a mixture o
vein of SCID mice (n = 4 per group), as described in Method Details. Similarly, SL
lungs were recovered at the time indicated and imaged to analyze the number of
coverage per field of view (FOV); n = 4 mice per group per time point ± SEMs. R
(G andH) Kaplan-Meier analysis of relapse-free survival of a curated cohort of ER+
low expressing as described in Method Details for TNFAIP3 (G) and SLC6A14 ex
(I) Correlation of SLC1A2 expression with response to AI in 52 paired ER+ breast c
significant decrease in SLC1A2 expression was observed in the responder grou
t test). ns, not significant. Each dot represents the value derived by a patient’s sp
(J) Correlation of the change in the SLC1A2 andAURKA expression levels followin
and p value are indicated in the figure).
114 Cell Reports 28, 104–118, July 2, 2019tween its role as an oncomiR or as a tumor suppressor. miR-
23b-enhanced expression levels were found in renal cell
carcinomas (Zaman et al., 2012), lymphomas (Li et al., 2013),
non-small-cell lung cancers (Begum et al., 2015), and pancreatic
cancers (Chen et al., 2017). Conversely, reduced levels were
found to be associated with colon cancer (Zhang et al., 2011)
and multiple myeloma (Fulciniti et al., 2016). Reduced levels of
miR-23b were found to promote the chemoresistance of gastric
cancers (An et al., 2015) and radioresistance in pancreatic can-
cers (Wang et al., 2013). An additional layer of complexity may
come from the 5p and 3p isoforms that could have indepen-
dent and/or opposing effects in different tissue contexts. Since
some of the above-mentioned studies did not dissect which of
the isoforms were predominant in the cohort of tumors analyzed,
some of the discrepancies observed may derive from such bias.
In this study, enhanced miR-23b-3p expression characterizes
ETR breast cancer cells and a subset of breast cancer patients
who show a worse prognosis. Since stable knockdown of miR-
23b-3p in vivo could be achieved only by concomitant downmo-
dulation of the 5p, we have opted for a short-term assay (i.e.,
quantification of residing cells in the lung after tail vein injection).
Lung retention assay has some limitations and does not recapit-
ulate the complex mechanism of the full metastatic cascade.
However, we have carefully selected the time point of the anal-
ysis such that the ability of a given cell to be retained is likely
due to the ability to survive and to colonize the lung. The priming
event that leads to miR-23b-3p-enhanced expression is the up-
regulation of the transcription factor GATA2 mediated by ER
signaling disengagement. GATA2 has been reported to favor
breast cancer progression (Wang et al., 2012) and to regulate
chemotherapy resistance and tumorigenicity in prostate cancer
(Vidal et al., 2015). Crucially, GATA2 silencing impairs the miR-
23b-3p-dependent amino acid transport regulation and ETR
cell survival and has a prognostic value in ER+ breast cancer.
miR-23b-3p-enhanced levels in ETR cells are paralleled by a
significant decrease in its target SLC6A14, an amino acid trans-
porter that has been demonstrated to be an ER-dependent gene,
and its expression was associated exclusively with ER+ breast
cancers. Moreover, SLC6A14 targeting is sufficient to induce
autophagy-dependent cell death in ER+ breast cancer models
(Karunakaran et al., 2011). Since the reduced expression levels
of SLC6A14 are compatible with ER+ ETR cell survival, it is plau-
sible that SLC6A14 downregulation may have been caused by a
miR-23b-3p-induced adaptation, thus establishing a metabolic
phenotype of the ETR cells that is characterized by enhanced
pro-survival autophagy and the reliance on another amino acid-targeting control (anti-miR-CTR, E). Cells were labeled with CellTracker dyes
f anti-miR-23b-3p and anti-miR-CTR transfected cells in a 1:1 ratio into the tail
C1A2 silenced (red) and siCTR transfected cells (green) were injected (F). The
fluorescent cells that colonize the lungs. Data shown are means for tumor cell
epresentative images are shown; scale bar, 200 mm. ***p < 0.001.
patients treatedwith tamoxifen in the adjuvant setting and divided into high and
pression (H). HR and log-rank Mantel-Cox p values are shown.
ancer samples pre- and post-2-week letrozole treatment (Miller et al., 2007). A
p, but no difference was found in the non-responder group (Wilcoxon paired
ecimen. Red lines connect the mean values pre- and post-letrozole treatment.
g adjuvant fulvestrant treatment (Geo: GSE33658, n = 11; Spearman correlation
transporter to compensate for the reduction in amino acid import
caused by SLC6A14 impairment. ETR cells and parental cells
show comparable cell growth rates and protein synthesis,
although the import of amino acids is reduced in ETR cells. We
hypothesized that autophagy could compensate for the reduced
amino acids import. However, amino acids uptake, although
significantly reduced, was not abolished, suggesting that other
amino acid transporters may still function in ETR cells. It has
been reported that glutamine can contribute to ETR cell survival
in an MYC-dependent mechanism (Shajahan-Haq et al., 2014)
and that autophagy activation could support tamoxifen resis-
tance (Cook et al., 2011). Moreover, tamoxifen resistance could
be supported by importing leucine in an LLGL2-dependent
fashion (Saito et al., 2019). Our data revealed that SLC1A2
expression and the subsequent increases in the intracellular
levels of aspartate and glutamate and uptake in ETR cells and
PDX models confer a catabolic and anabolic advantage to ETR
breast cancers.
Our analyses show that both autophagy and aspartate and
glutamate uploaded together establish a metabolic condition
that sustains resistance to ET. Although this phenomenon
should warrant further investigation, a potential explanation of
the need for both autophagy and selective amino acid import
may come from the reduction in essential amino acid levels
that we have observed following autophagy inhibition. In this
context, the aspartate and glutamate that are not affected by
autophagy inhibition could be used to derive all of the other
non-essential amino acids. In addition, glutamate and aspartate
import could mitigate the effects caused by a severe decrease
in the intracellular levels of amino acids, an established activator
of autophagy (Galluzzi et al., 2014), to modulate the flux. This
promotes a pro-survival autophagy, without the activation of a
pro-apoptotic autophagic flux, which has been reported after
the acute targeting of SLC6A14. In addition, in silico analysis
of the METABRIC database (Pereira et al., 2016) shows that
SLC1A2 and SLC6A14 are not concomitantly overexpressed
or amplified in breast cancers and may be mutually exclusive
(Figure S7D). It is interesting to note that SLC1A2 expression
has been reported to play a role in different cancers. SLC1A2
undergoes a genomic breakpoint in its 50 region and forms a
fusion gene with CD44 in gastric and colorectal cancers (Tao
et al., 2011; Shinmura et al., 2015). The CD44-SLC1A2 aberra-
tion induces higher glutamate intracellular levels, and SLC1A2
targeting resensitizes tumors to chemotherapy (Tao et al.,
2011). Similarly, the enhanced levels of SLC1A2 in the ETR
breast cancer models resulted in a significant increase in intra-
cellular and intratumoral aspartate and glutamate levels. Once
targeted, ETR cellular aggressive features are reduced and cells
are resensitized to ET. Although we did not investigate the po-
tential fusion gene in the ETR models analyzed, gene expression
profiling revealed that CD44 expression is upregulated in LTED
cells (7.3-fold when compared to parental MCF7), and therefore
it would be interesting to investigate whether a CD44-SLC1A2
fusion may also occur in ETR breast cancer models. The role
of aspartate in cancer has been recently explained by the sem-
inal work of the Vander Heiden group (Sullivan et al., 2015).
Initially, Sullivan et al. (2015) demonstrated that in oxidative
phosphorylation (OXPHOS)-proficient cells, respiration servesto fuel electron acceptors for aspartate synthesis, and aspar-
tate supplementation is sufficient to sustain proliferation in
OXPHOS-deficient cells (Tao et al., 2011). More recently, 2 inde-
pendent studies revealed that aspartate availability is a meta-
bolic limitation that tumors experience and that overcoming
this limitation, either via aspartate upload via SLC1A3 (Garcia-
Bermudez et al., 2018) or via the conversion of asparagine
into aspartate (Sullivan et al., 2018), is advantageous for tumor
growth. Previous studies have reported that metformin anti-tu-
mor activity correlates with a diminution of NAD+ and aspartate
in tumors (Gui et al., 2016), and these findings indicate that
aspartate limitation is required for the anti-tumor efficacy of
metformin and, broadly, other biguanides. We have previously
reported that metformin was ineffective in AI-resistant models
(Bacci et al., 2016), and this can now be explained by the
enhanced SLC1A2-dependent aspartate-boosting mechanism
that maintains aspartate homeostasis. Therefore, lowering
aspartate intratumoral levels may be of benefit in ETR. However,
as confirmed in our study, SLC1A2 can also serve for glutamate
import, and only the concomitant deprivation of both amino
acids was able to reduce the mitochondrial potential and OCR
of the resistant cells. However, even if the glutamate contribu-
tion seems lower than that of aspartate by 14C tracing experi-
ments, flux analysis using U-13C-glutamate revealed a role for
glutamate in anabolism, which is able to sustain not only DNA
biosynthetic pathways but also lipid and protein biosynthesis.
This anabolic supporting role of aspartate and glutamate is in
line with previous reports showing that the majority of carbon
mass in cells is derived from amino acids rather than glucose
or glutamine (Hosios et al., 2016).
In conclusion, the experimental and clinical data herein pre-
sented support a role for amino acid metabolism and availability
in promoting ETR. The findings provide mechanistic insights into
the metabolic deregulation of ETR and a series of molecular
players that could be useful in identifying a signature for breast
cancer patients with an increased risk of ETR. This is particularly
pertinent given that the majority of ER+ breast cancer patients
will undergo ET and that the identification of resistant patients
is an important and still unmet clinical issue.STAR+METHODS
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HCC1428 ATCC Cat# CRL-2327
LTED Cells Bacci et al., 2016 N/A
MCF7-TAMR This paper N/A
MCF7-FULVR This paper N/A
Experimental Models: Organisms/Strains
BALB/c mice Charles River Laboratories Cat# 236CB17SCID
NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) Simo˜es et al., 2015 N/A
Oligonucleotides
anti-miR-23b-3p Ambion Cat# MH10711
siSLC1A2 Sigma Cat# Hs01_00109453
siCTR Sigma Cat# SIC001
anti-miR-negative control (anti-miR-CTR) Ambion Cat# AM17011
siGATA2 Sigma Cat# Hs01_00106117
siATG7_71 Sigma Cat# Hs02_00341471
siATG7_49 Sigma Cat# Hs01_00077649
siATG7_48 Sigma Cat# Hs01_00077648
SLC6A14 (Hs00924564_m1) Applied Biosystems Cat# 4448892
SLC1A2 (Hs01102423_m1) Applied Biosystems Cat# 4448892
GATA2 (Hs00231119_m1) Applied Biosystems Cat# 4453320
GAPDH (Hs02786624_g1) Applied Biosystems Cat# 4331182
ACTB (Id:Hs99999903_m1) Applied Biosystems Cat# 4331182
miR-23b-3-p (000400) Applied Biosystems Cat# 4427975
RNU48 (001006) Applied Biosystems Cat# 4427975
U6 (001973) Applied Biosystems Cat# 4427975
TNFAIP3 precast primer (HsaCID0012648) Bio-Rad Cat# 10025636
Beclin-1 precast primer (HsaCID0016032) Bio-Rad Cat# 10025636
GAPDH precast primer (HsaCED0038674) Bio-Rad Cat# 10025636
Software and Algorithms
Masshunter Quantitative Analysis Software Agilent Technologies RRID: SCR_015040
Masshunter Qualitative Analysis Agilent Technologies RRID:SCR_016657
Fihen Metabolomics RTL library Agilent Technologies Cat# G1676AA
7500 Real-Time PCR Software Applied Biosystems RRID:SCR_014596
Thermo XCalibur Quan Browser software Thermo Fisher Scientific RRID: SCR_014593
FiJi https://fiji.sc N/A
GraphPad Prism v8.0c https://www.graphpad.com/ N/A
KM plotter Gyo¨rffy et al., 2010; La´nczky et al., 2016 http://kmplot.com/analysis/
cBioPortal https://www.cbioportal.org/ RRID:SCR_014555
Firebrowse http://firebrowse.org/ N/A
Seahorse Wave software Agilent Technologies RRID:SCR_014526
GeneSpring GX v.14.8 software Agilent Technologies RRID:SCR_010972
R Statistical Software https://www.r-project.org/ N/ALEAD CONTACT AND MATERIALS AVAILABILITY
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Culture
MCF7, ZR75.1 and HCC1428 human female breast cancer cells were obtained from ATCC and cultured in phenol red-free RPMI
1640 medium (GIBCO #11835-063) supplemented with 10% fetal bovine serum (FBS, Euroclone #ECS0180L) 2 mmol/L glutamine
(Sigma #G7513) and 1 nmol/L 17b-estradiol (E2, Sigma #E2758). The corresponding LTED (long term estrogen deprived) derivatives
were maintained in sterol-deprived medium in phenol red–free RPMI1640 medium containing 10% dextran charcoal-stripped FBS
(Hyclone #SH30068.03) and 2 mmol/L glutamine (DCC medium). Tamoxifen- (TAMR) and fulvestrant- (FULVR) resistant cells were
cultured in DCC medium supplemented with 1 mmol/L 4-OH tamoxifen (Sigma #H7904) or 100 nmol/L fulvestrant (Sigma #I4409),
respectively. Cells were short tandem repeat tested, amplified, stocked, routinely subjected tomycoplasma testing and once thawed
were kept in culture for a maximum of 20 passages.
Mouse models and care
5- to 6-week-old female BALB/c mice were purchased from Charles River Laboratories (236CB17SCID) and used for tail vein injec-
tion experiments. Animal work was carried out under the Project licenses 1002/2017-PR and was approved by the Ministero della
Salute. All animals were monitored by staff from the Centro Stabulazione Animali da Laboratorio (CESAL) for signs of ill health.
Mice were housed under sterile conditions (five or less animals per cage) with ad libitium access to food and water.
For patient-derived xenografts (PDX), mouse studies were conducted in accordance with the UK Home Office Animals (Scientific
Procedures) Act 1986, using 8- to 10-week-old NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) female mice at the University of Manches-
ter. HBCx34 and HBCx34 TAMR PDXs have been established as previously described (Cottu et al., 2014). Serial passaging of the
PDXwas carried out by implanting small fragments of the tumor subcutaneously into dorsal flanks of NSGmice. HBCx34 breast can-
cer estrogen-dependent PDXs were administered with 8 mg/ml of E2 in drinking water at all times. HBCx34 TAMR PDXs were treated
for the entire duration of the experiments in the presence of tamoxifen (10 mg/kg/day, oral gavage). Experiments were performed
using PDX tumors between passages 5 and 8. Animal weight and tumor size were measured twice a week. Tumor chunks were
snap frozen and further processed for either RNA extraction and qRT-PCR analysis or GC-MS.
METHOD DETAILS
Cell viability assay
Sensitive and resistant cells were seeded into 12 well plates in either standard conditions (see cell culture) or experimental conditions
such as in the presence of 25 mmol/l of the autophagy inhibitor CQ (Sigma #C6628). 5 days post seeding cells, plates were stained
with crystal violet (triphenylmethane dye 4-[(4-dimethylaminophenyl)-phenyl-methyl]-N,N-dymethyl-alanine; Sigma #548-62-9),
dried overnight and the crystal violet within the adherent cells solubilized with 500 ml/well of 2% SDS. The absorbance at 595 nm
was evaluated using a microplate reader.
MTT assay
Sensitive and resistant cells transfected using siRNA against ATG7 were seeded into 24 well plates in standard medium (see cell cul-
ture). 48 hours after transfection cells were subjected to the colorimetric non-radioactive quantification of cell proliferation and
viability using MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay (0,2mg/ml, Sigma #M5655). MTT was
added into the medium of each well and after 2 hours at 37C, the cells were extensively washed with PBS, allow to dry and then
200 mL of DMSOwas added to resuspended the amount ofMTTwithin the cells and 100 mLwas subjected to absorbance wavelength
evaluation at 565 nm using a microplate reader.
Colony formation assay
To evaluate clonogenicity of breast cancer cells under stress conditions, 0.5-1 3 103 cells were seeded per well in a 6 well plate in
either the recommended medium conditions or experimental conditions such as amino acids deprivation. 15 days post seeding, the
colonies were fixed with 4% formaldehyde and stained with crystal violet staining solution. Air-dried plates were scanned at 600 dpi
and images analyzed using FiJi.
Transwell invasion assay
Invasion assay was performed using 8-mm-pore transwells (Corning #3428) coated with 10 mg/cm2 of reconstituted standard
formulation Matrigel (BD Biosciences #356334). Transfected cells (using anti-miR-23b-3p, siSLC1A2 and relative controls oligos)
were serum starved for 6 hours and then 1 3 105 cells seeded onto the upper chamber of the transwell in serum-free medium
and allow to invade overnight toward complete medium. Air-dried membranes stained with DiffQuick solution (BD Biosciences
#726443) were imaged and invasion was evaluated by counting the cells migrated to the lower surface of the filters (six randomly
chosen fields).e4 Cell Reports 28, 104–118.e1–e8, July 2, 2019
Protein de novo synthesis assay
To analyze protein de novo synthesis rate in resistant cells compared to parental cells, 33 104 cells were seeded per well in a 96 well
clear bottomblack plate (Corning #3603). The following day, the culturemedia were removed and cells were incubated for 30minutes
in fresh culture medium containing O-Propargyl-Puromycin (OPP) with or without 50 mg/ml cycloheximide. OPP incorporates into the
C terminus of translating polypeptide chains, thereby stopping translation. The truncated C-terminal alkyne-labeled proteins can
subsequently be detected via copper-catalyzed click chemistry (Liu et al., 2012). Cells were then processed for detection of protein
synthesis according to the protocol of Cayman Chemicals Protein Synthesis assay (Cayman Chemicals #601100).
RNAi transfection
Cells were transfected with 15 nmol/L anti-miR-23b-3p (MH10711, Ambion), with 45 nmol/L siSLC1A2 (Hs01_00109453, Sigma),
siGATA2 (Hs01_00106117, Sigma), or siATG7 (Hs02_00341471, Hs01_00077649, or Hs01_00077648, Sigma) and respective nega-
tive controls (AM17011, Ambion; SIC001, Sigma) using Lipofectamine RNAiMAX Reagent (Thermo Fisher Scientific #13778-150) and
Opti-MEM (GIBCO #31985062) accordingly to manufacturer’s instructions and analysis was performed 3 days after transfection.
Radioactive assays
Breast cancer cells were treated as described in the figures for 3 days (see RNAi transfection). Aspartic acid, glutamic acid or amino
acids uptake was evaluated incubating the cells with uptake buffer solution (140 mmol/L NaCl, 20 mmol/L HEPES/Na, 2.5 mmol/L
MgSO4, 1 mmol/L CaCl2, and 5 mmol/L KCl, pH 7.4) containing [U-
14C] radioactive metabolites for 15 minutes. Cells were subse-
quently washed with ice cold PBS and lysed with 0.1 mol/L NaOH.
To analyze the incorporation of radioactive amino acids into proteins, lipids or DNA, culture media were changed to a deprived-
DMEM medium (GIBCO #A14430-01) with or without non-radioactive amino acids in the presence of 10% DCC, 11 mM glucose,
2 mmol/L glutamine and then supplemented with 1 mCi 14C-aspartic acid (Perkin Elmer # NEC268E050UC) or 1.5 mCi 14C-glutamic
acid (Perkin Elmer # NEC850E050UC) 24 hours prior to the end of the experiment. For radioactive incorporation into proteins, cells
were washed in ice cold PBS and then resuspended in 20% trichloroacetic acid, placed on ice for 30 minutes and centrifuged
(10000 rpm for 10 minutes at 4C). Pellet was resuspended in dH2O, transferred to a scintillation vial and counted on the scintillation
counter. For fatty acids synthesis analysis, cells were washed three times in ice cold PBS and then lysed in methanol. Samples were
first resuspended in 4 volumes of a CHCl3:MeOH (1:1) solution and then an additional volume of dH2O was added. The solution was
then centrifuged at 1000 rpm for 5 minutes at room temperature. The lower phase was collected, transferred to a scintillation vial
and counted on the scintillation counter. For DNA incorporation analysis, cells were washed and then resuspended in Tris-Hcl
50mM/EDTA 100mM/SDS 0.5%/proteinase K lysis buffer. Samples were added to one volume of phenol:chloroform:isoamyl alcohol
(25:24:1), mixed and centrifuged (10000 rpm for 10 minutes at room temperature). The upper aqueous phase was collected, resus-
pended in 1/10 volume of 3 M NH4OAc and 2 volumes of ethanol and incubated for 3 hours at 80C. The precipitated DNA was
pelleted (10000 rpm for 10 minutes at room temperature), washed with 70% ethanol and allowed to dry. The pellet was resuspended
in dH2O and transferred to a scintillation vial and counted on the scintillation counter. All the radioactive signals were normalized on
protein content.
Immunoblotting and immunoprecipitation
Cells were lysed using cold RIPA buffer (50 mM Tris Hcl pH7.5, 150 mM NaCL, 1% Nonidet P-40,2 mM EGTA, 1 mM sodium orto-
vanadate, 100mMNaF) supplemented with protease inhibitors (Sigma # P8340) and protein concentrations of lysate were measured
by Bradford method (Bio-Rad Protein Assay #500-006), 20-40 mg of total proteins were loaded in precast SDS-PAGE gels (Biorad
#456-8096) and then transferred onto nitrocellulose membrane by Trans-Blot Turbo Transfer Pack (Biorad #1704157). The immuno-
blots were incubated in non-fat dry milk 2%, tween 20 0.05% in PBS at room temperature and probed with primary and appropriate
secondary antibodies. The antibodies used in immunoblotting were GATA2 (Cell Signaling, #4595S) and SLC1A2 (Santa Cruz
Biotechnology, #sc-365634), SLC6A14 (Abcam, #ab99102), beclin-1 (Invitrogen, #PA1-16857), LC3 (Invitrogen, #PA1-16930) and
ubiquitin-K63 (Thermo Fisher, #14-6077-80), APG7 (Santa Cruz Biotechnology, #sc-376212), tubulin (Sigma, #T5168).
Immunoprecipitation was performed using the Protein A/G-PLUS Agarose beads (Santa Cruz Biotechnology #sc-2003) according
to the manufacturer’s instructions. Briefly, 300 mg of cell lysate were incubated overnight with beclin-1 antibody (Santa Cruz Biotech-
nology, sc-48341) prior to incubating the protein:antibody complex with the beads. Immunoprecipitated proteins:antibody:beads
complexes were dissociated using Laemmli buffer (Bio-Rad #161-0737) and subjected to SDS-PAGE.
Immunofluorescence
Glass coverslip (Nunc LabTek Chambered CoverGlass, Thermo Scientific)-plated cells were fixed with 4% formaldehyde for
1 hours, then permeabilized with 0.1% Triton in PBS before incubation with primary antibodies. Primary antibodies were diluted
in blocking solution 1/400 (1% BSA and 2% serum in PBS) and incubated overnight at 4C. Secondary antibodies conjugated
with Alexa Fluor 488 (Life Technologies, goat anti-rabbit #A-11034) or 633 (Life Technologies, goat anti-rabbit #A-21071) were diluted
in blocking solution (1/1000) and incubated for 1 hour at room temperature. All fluorescence samples were examined at room tem-
perature using a microscope (TCS SP5; Leica) with lasers exciting at 488, 543, and 633 nm (Leica). Lasers and spectral detection
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images were collected simultaneously in two or three channels. Images were taken using a 20x/NA/air 40x/1.25 NA oil HCX Plan Apo
and 63x, 1.4–0.6 NA, oil, HCX Plan APO lens. Images were captured using the Leica LAS-AF image acquisition software. Overlays
were generated using LAS-AF software. Photo montages were generated using LAS-AF, but were not further processed. The quan-
tification was performed using FiJi: an outline was drawn around each cell and spots were counted in at least 50 cells derived from
three representative 63x images from 3 independent experiments (one per experiment).
Real Time RT-PCR (qRT-PCR) and miRNA analysis
Total RNA, including small RNAs, was extracted usingmiRNeasy (QIAGEN #217004), quantified and 500 ngwere reverse transcribed
using the QuantiTect high capacity cDNA reverse transcription kit (QIAGEN #205311), for mRNA analysis, or 10 ng using Taqman
MicroRNA Reverse Transcription Kit (Applied Biosystems #43665967), for miRNA analysis. qRT-PCR was done using a 7500 Fast
Real Time PCR system (Applied Biosystems) using Taqman gene/microRNA assays (Applied Biosystems), respectively. The probes
used in the work are: SLC6A14 (Hs00924564_m1), SLC1A2 (Hs01102423_m1), GATA2 (Hs00231119_m1) and endogenous controls
GAPDH (Hs02786624_g1) and ACTB (Hs99999903_m1)) for mRNA analysis. For microRNA assay the probes used are miR-23b-3p
(ID:000400), and endogenous control RNU 48 (ID:001006) and U6 (ID:001973). TNFAIP3 (HsaCID0012648, Bio-Rad) and beclin-1
(HsaCID0016032, Bio-Rad) mRNA expression analysis was performed using SYBR green dye precast primers (Bio-Rad) and normal-
ized on the results obtained using GAPDH (HsaCED0038674, Bio-Rad). The relative quantity was determined using DDCt, according
to the manufacturer’s instructions (Applied Biosystems).
Seahorse XF MitoStress Test
Cells were seeded in XFe96 cell culture plates with 1.5-23 104 cells per well in 80 mL of culture medium and incubated at 37C (5-8
technical replicates). 24 hours post seeding medium was replaced with 180 mL XF base medium supplemented with 25 mM glucose
(Sigma #G8644), 2 mM glutamine, 1 mM sodium pyruvate (Sigma #S8636). Cells were incubated for 1 hour at 37C in atmospheric
CO2 to allow the cells to pre-equilibrate with the XF base medium. An accurate titration with the uncoupler FCCP was performed
for each cell type. Together with OCR measurement, values of ECAR were also recorded. Addition of Aspartate (0.15 mM,
Sigma #A9256), Glutamate (0.13 mM Sigma #G1001), the ATP synthase inhibitor oligomycin (0.8 mM), the proton uncoupler FCCP
(0.5-1 mM), the respiratory complex I inhibitor rotenone (1 mM), and the respiratory complex III inhibitor antimycin A (1 mM) was carried
out at the times indicated. Protein quantification was used to normalize the results. Basal respiration is calculated as last rate mea-
surement before injection – non-mitochondrial respiration rate. Maximal respiration is calculated as the maximum rate measurement
after FCCP injection – non-mitochondrial respiration.
High-performance liquid chromatography (HPLC)
Amino acids extraction was performed as reported by Nemkov et al. (2015). Briefly, cell pellets were extracted immediately before
analysis in ice-cold lysis/extraction buffer (methanol/acetonitrile/water, 5/3/2 v/v, Sigma) at a ratio of 2 3 106 cells/ml. Tubes were
first agitated at 4C for 30 minutes and then centrifuged at 4C, 10000 g for 10 minutes. The recovered supernatants were subjected
to precolumn derivatization of amino acids using 4-N,N-dimethylaminoazobenzene-4’-sulfonyl chloride (Supelco #502219) following
the manufacture instructions (DABS, Sigma). DABS-amino acids were detected at visible light wavelengths (436nm) using a DIONEX
P680-UVD170U HPLC system (column: Kinetex 5mm C18 100 A˚ LC column 250x4.6mm; mobile phase: A = KH2PO4 25mM pH 6.8
(Sigma), B = acetonitrile (Sigma #34851); gradient program (time:%B): 0-5 min: 20%; 5-9 min: 25%; 9-15 min: 25%; 15-18 min 30%;
18-22 30%; 22-27 35%; 27-35 60%; 35-43 70%; flow rate: 0.8ml/min; injection volume: 10ml). A reference amino acids spectrumwas
obtained by titrating a mixture of amino acids of known concentration (Sigma # A9781).
Gas chromatography–MS (GC-MS)
Snap frozen tissue samples were minced and subjected to extraction using a mixture of CHCl3:MeOH:H2O (Sigma #34854-1 and
#900688-1, Merck #102699-1000) (1:1:1). Minced tissues were quenched with 0.4 mL ice cold methanol and an equal volume of
water containing 1 mg norvaline (Sigma #53721), used as internal standard. One volume of chloroform was added, and the samples
were vortexed at 4C for 30 minutes. Samples were centrifuged at 3000 g for 10 minutes, and the aqueous phase was collected in a
new tube and evaporated at room temperature. Dried polar metabolites were dissolved in 60 mL of 2%methoxyamine hydrochloride
(Sigma #226904) in pyridine (25104 Thermo), and held at 30C for 2 hours. After dissolution and reaction, 90 mL MSTFA + 1% TMCS
(69478-10x Sigma) were added and samples were incubated at 37C for 60minutes. Gas chromatographic runs were performedwith
helium as carrier gas at 0.6 mL/min. The split inlet temperature was set to 250C and the injection volume of 1 mL. A split ratio of 1:10
was used. The GC oven temperature ramp was from 60C to 325C at 10C/min. The data acquisition rate was 10 Hz. For the Quad-
rupole, an EI source (70 eV) was used, and full-scan spectra (mass range from 50 to 600) were recorded in the positive ion mode. The
ion source and transfer line temperatures were set, respectively, to 250C and 290C. TheMassHunter data processing tool (Agilent)
was used to obtain a global metabolic profiling. Fihen Metabolomics RTL library (Agilent G1676AA)
13C-tracing experiments using liquid-chromatography-MS (LC-MS)
Parental and LTEDMCF7 cells were incubated for 48 hours with 0.15 mM [U-13C]-aspartic acid (Cambridge Isotope Laboratories) or
0.13 mM [U-13C]-L-glutamic acid (Sigma Aldrich). The cells were washed once with ice cold 0.9% NaCl solution. The metabolitee6 Cell Reports 28, 104–118.e1–e8, July 2, 2019
extraction was performed using 80% methanol. After 5 minutes of incubation cells were scraped and collected in a new tube.
Following a centrifugation at 20000 g for 10 minutes at 4C, the supernatant was transferred to a new vial for MS analysis. Pellet
was used for protein quantification. 5 ml of each sample was loaded into a Dionex UltiMate 3000 LC System (Thermo Scientific Bre-
men) equipped with a C-18 column (Acquity UPLC -HSS T3 1. 8 mm; 2.13 150 mm, Waters) coupled to a Q Exactive Orbitrap mass
spectrometer (Thermo Scientific) operating in negative ion mode. A step gradient was carried out using solvent A (10 mM TBA and
15 mM acetic acid) and solvent B (100% methanol). The gradient started with 0% of solvent B and 100% solvent A and remained at
0%B until 2 minutes post injection. A linear gradient to 37%Bwas carried out until 7 minutes and increased to 41% until 14 minutes.
Between 14 and 26 minutes the gradient increased to 100% of B and remained at 100% B for 4 minutes. At 30 minutes the gradient
returned to 0% B. The chromatography was stopped at 40 minutes. The flow was kept constant at 250 mL/min and the column was
placed at 25C throughout the analysis. The MS operated in full scan - SIM (negative mode) using a spray voltage of 3.2 kV, capillary
temperature of 320C, sheath gas at 10.0, auxiliary gas at 5.0. For full scan - SIMmode, AGC target was set at 1e6 using a resolution
of 70.000, with a maximum IT of 256 ms. For the data analyses we integrated the peak areas using the Thermo XCalibur Quan
Browser software (Thermo Scientific).
Lung retention assay
MCF7-LTED anti-miR-CTR, anti-miR-23b-3p, siCTR and siSLC1A2 cells were labeled with CellTracker Red CMTPX or Green
CMFDA dyes (Molecular Probes), trypsinized, mixed at a 1:1 ratio, and a total of 1 3 106 cells injected into the tail veins of 5- to
6-week-old BALB/c mice. Mice were sacrificed at 1 and 5 hours post injection, and lungs were examined on a Leica TCS SP5 mi-
croscope using x10 lens. Six images were taken for each lung. Tumor cell colonization of the lung was quantified in the Fiji open plat-
form for image analysis, by converting the red and green images into separate binary images andmeasuring total tumor cell coverage
per field of view.
Gene and miRNA expression analysis
MCF7 cells were cultured in either the recommended medium conditions or E2 deprived for 3 days and compared to MCF7-LTED
cells cultured in standard medium. Triplicate samples from 3 independent experiments were assessed for global miRNA and gene
expression by Microarrays. Specifically, 9 samples were hybridized on Agilent whole human genome microarray (Agilent Technolo-
gies #G4851A), which represents 60k unique human transcripts. The same samples were hybridized also on Agilent human miRNA
microarray v16 (Agilent Technologies #G4870A). One-color gene expression was performed according to the manufacturer’s pro-
cedure as previously described (Ferracin et al., 2013).
Bioinformatic analyses
Microarray data were normalized and analyzed using GeneSpring GX v.14.8 software (Agilent Technologies). Data transformation
was applied to set all the negative raw values at 1.0, then the quantile normalization was applied. The probes detected in at least
one sample were used for statistical analyses. Differentially expressed genes were selected to have aR 2-fold expression difference
between groups and an adjusted P-value% 0.05 at ANOVA test, with Benjamini and Hoechberg correction. Supervised hierarchical
clustering was performed for OS samples with GeneSpring clustering tool using the list of differentially expressed genes and
Euclidean correlation as a measure of similarity.
The mRNA and miRNA anti-correlation network analyses described in Figure 1C were performed using the R software. Briefly,
mRNAs and miRNAs found as differentially expressed in each pairwise comparison (FDR < 0.05, FC < 2 or > 2) were initially
used to filter candidate interactors emerging from the PITA miRNA/target predictor tool (Kertesz et al., 2007). To ensure the identi-
fication of relevant interactors and limit the size of the network, the filtered collection of mRNA/miRNA pairs was further purged from
experimentally validated pairs, according to the miRTarBase repository (Chou et al., 2018). The expression values of the remaining
candidate interactors (taken from the whole set of samples rather than from those relevant for the differentially expressed analysis)
were tested for mRNA/miRNA expression anti-correlation (correlation test, Benjamini-Hochberg correction, adjusted p < 0.05 and
correlation < 0). The resulting networks were graphically annotated and represented using functions from the igraph R package.
Analysis of human datasets
The BRCA TCGA dataset analyzed in Figures 1A, 1B, and 4I is available in The Cancer Genome Atlas (TCGA) data portal (https://
www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga). Gene and miRNA expression data and the
corresponding clinical information for ER+ BRCA from TCGA provisional dataset were obtained through Firebrowse (http://
firebrowse.org/) data portal. The normalized reads count for mRNA (RSEM) and mature miRNAs (RPM) were downloaded and
log2 transformed. From the BRCA dataset, we selected samples with miRNA-mRNA and overall survival (OS) data. Survival analysis
was performed using Kaplan-Meier curve log-rank testing, using Cutoff finder (Budczies et al., 2012) for best miR-23b-3p/SLCA6A14
high- and low-expression selection. For mRNA analysis in Figure S1C, overall survival (OS) of untreated breast cancer patients
belonging to the METABRIC dataset were retrieved using Km-plotter (http://kmplot.com) (La´nczky et al., 2016). For SLC6A14 (Fig-
ure S1B), TNFAIP3 (Figure S1E) survival analysis, the curated dataset of ER+ breast cancers was created using Km-plotter and
included the relapse free survival data of patients belonging to the following datasets: GSE6532 (Loi et al., 2007), GSE20711 (Dedeur-
waerder et al., 2011), GSE7390 (Desmedt et al., 2007), GSE21653 (Sabatier et al., 2011), E-MTAB-365 (Re`me et al., 2013), GSE2034Cell Reports 28, 104–118.e1–e8, July 2, 2019 e7
(Wang et al., 2005), GSE2990 (Sotiriou et al., 2006), GSE17705 (Symmans et al., 2010), GSE12093 (Zhang et al., 2009), GSE9195 (Loi
et al., 2008), GSE3494 (Miller et al., 2005), GSE4611 (Karn et al., 2010), GSE45255 (Nagalla et al., 2013), GSE2603 (Minn et al., 2005),
GSE16391 (Desmedt et al., 2009), GSE42568 (Clarke et al., 2013), GSE26971 (Filipits et al., 2011) and GSE19615 (Li et al., 2010).
For GATA2 (209710_at; Figure 3I) overall survival analysis the curated dataset comprises the following datasets: GSE20711,
GSE7390, GSE45255, GSE42568, GSE3494. For SLC6A14 (219795_at; Figure 7G), TNFAIP3 (202643_s_at; Figure 7H) survival anal-
ysis, the curated dataset of ER+ breast cancers that have been treated with adjuvant tamoxifen was created using Km-plotter and
included patients that belong to the following datasets GSE6532, GSE2990, GSE17705, GSE12093, GSE9195, GSE45255,
GSE16391, GSE3494, GSE26971 and GSE19615. SLC1A2 data in 52 paired ER+ breast cancer samples pre- and post-2-week le-
trozole treatment (Figure 7I) were retrieved using GEO (GSE5462) (Miller et al., 2007) and normalized log2 expression values are
shown either pre- or post letrozole treatment for each patient. Correlation data on patients that have been treated with adjuvant ful-
vestrant (Figure 7J) were from the GSE33658 dataset (Massarweh et al., 2011). SLC1A2 and AURKA log2 normalized expression
levels were reported. Changes were obtained by subtracting from the expression value of tumor that have been treated with fulves-
trant that of baseline expression. Correlation analysis was performed using Spearman correlation test.
QUANTITATION AND STATISTICAL ANALYSIS
Statistics were performed using GraphPad Prism 8. Unless stated otherwise, all numerical data are expressed as the mean ± error of
the mean (SEM) and noted in figure legends. Unless stated otherwise, comparisons between 2 groups were made using the two-
tailed, unpaired Student’s t test. Comparisons between multiple groups were made using one-way analysis of variance (ANOVA),
and two-way ANOVA for comparisons between multiple groups with independent variables. Bonferroni post-testing (unless other-
wise stated) with a confidence interval of 95% was used for individual comparisons. Multivariate Cox Analyses on the cohort of pa-
tients analyzed in Figure 7G and 7H were generated using KM-plotter and are reported in Table S3. Statistical significance was
defined as: *, p < 0.05; **, p < 0.01; ***, p < 0.001; ns, not significant.
DATA AND CODE AVAILABILITY
mRNA and miRNA data derived from microarray analysis are deposited in NCBI Gene Expression Omnibus (GEO) database: acces-
sion number GSE120931. Feature Extraction 10.7.3.1 software (Agilent Technologies) was used to obtain the microarray raw-data
and data.
The R script (mM_Net.R) for the interactor network analysis displayed in Figure 1C is available and can be downloaded (https://
github.com/matteoramazzotti/TransTools).e8 Cell Reports 28, 104–118.e1–e8, July 2, 2019
